TAKE A NOTE OF THIS UPCOMING MEETING IN BOSTON, LA BELLE VILLE!

Dear MUTOMBO,

A couple of weeks ago I released the final agenda for NGS for Cancer Drug Development. Since this meeting is all about bringing you the latest results from the most recent clinical trials, I thought I’d highlight today some of the exclusive data not available at any other drug development meeting… Christopher Maher from Washington University delves deep into his group’s work on the discovery of druggable gene fusions in solid tumors, and prioritizing clinically meaningful therapeutics targets George Mulligan, Director of Translational Medicine at Millennium walks through the treatment of myeloma and mantle cell lymphoma with Velcade, and how his group are using NGS in the clinic for accurate patient subgroup selection Joel Parker from the University of North Carolina releases exclusive data from his recent research applying mRNA–sequencing analysis in breast cancer to explore isoform switching and mutation expression Brian Dougherty, Translational Genomics Lead, Oncology at AstraZeneca talks in detail about how his team are applying NGS to develop biomarkers and optimize patient stratification efforts   The agenda is packed full of cutting edge data from leading oncology experts using NGS as an integral technology in their research efforts Download the brochure for more details on the data packed sessions. This is the number one opportunity to discover how pharma are using the latest cutting-edge NGS technologies in oncology, but more importantly how you can learn from them and best apply NGS in your cancer drug discovery and development efforts. So that’s it in a nutshell. If you want to keep up to speed with leading pharma and get the most out of your sequencing projects, be sure to make time to attend NGS for Cancer Drug Development in Boston in September. You can secure your place at www.ngs-cancer.com/register Thank you, and see you in Boston. Kind regards, Izzy Izzy Scott-Moncrieff Hanson Wade